Instrument Inactif

Communiqués IsoPlexis Corporation

Actions

ISO

US4650051067

Equipement et technologie médicale avancés

Communiqués

21/03/23	Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company	PR
16/03/23	ISOPLEXIS CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
09/03/23	ISOPLEXIS CORP : Other Events (form 8-K)	AQ
16/02/23	ISOPLEXIS CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
14/02/23	ISOPLEXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IsoPlexis Corporation - ISO	BU
12/01/23	IsoPlexis Reports Preliminary Full Year 2022 Revenue	GL
30/12/22	ISOPLEXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IsoPlexis Corporation - ISO	BU
21/12/22	ISOPLEXIS CORP : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21/12/22	Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company	GL
21/12/22	Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company	PR
17/11/22	Published in Journal for Immunotherapy of Cancer: Using Single-Cell Analysis to Assess the Effects of an Anti-OX40 Monoclonal Antibody in Its First-in-Human Phase I/II Study for Advanced Solid Cancer	PU
10/11/22	ISOPLEXIS CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
10/11/22	IsoPlexis Reports Third Quarter 2022 Financial Results	GL
09/11/22	IsoPlexis to Participate in Upcoming Investor Conferences	GL
19/10/22	IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022	GL
13/09/22	IsoPlexis Announces First APAC Publication, Illustrating Early Impact of Codeplex Platform	AQ
13/09/22	IsoPlexis Announces First APAC Publication, Illustrating Early Impact of Codeplex Platform	GL
12/09/22	ISOPLEXIS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
06/09/22	IsoPlexis Partners with MediMergent and The Center for Cancer and Blood Disorders in Study of AZD7442 for Prevention of COVID-19 Infection in Immuno-Compromised Cancer Patients	GL
31/08/22	IsoPlexis to Participate in the Morgan Stanley Global Healthcare Conference	GL
23/08/22	IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum “Homi” Shamir to its Board of Directors	AQ
23/08/22	IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum “Homi” Shamir to its Board of Directors	GL
23/08/22	ISOPLEXIS CORP : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
15/08/22	ISOPLEXIS CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
10/08/22	IsoPlexis : Reports Second Quarter 2022 Financial Results - Form 8-K	PU